Should the elderly hypertensive be treated? Evidence from clinical trials
- 1 November 1987
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 147 (11) , 1933-1937
- https://doi.org/10.1001/archinte.147.11.1933
Abstract
Clinical trials for over 15 years have addressed the therapeutic utility of treating elderly hypertensives. Many early trails showed no treatment effects. Because of the recent publication of new information, a review of available evidence concerning this issue was undertaken. Eight randomized clinical trials were assessed regarding trial design. The studies varied according to generalizability, diagnostic criteria, choice of therapy, outcome measures assessed, evaluation of compliance, methods of analysis, duration of follow-up, determination of side effects, and ability to exclude a type 2 error. While many of the earlier studies found no treatment effects, they lacked methodologic rigor; more recent studies demonstrated positive treatment effects. Pooling of results from similar trials supports a notable treatment effect in the prevention of stroke. There is also evidence that the ederly are not more susceptible to side effects of antihypertensive drugs, as is generally believed. The best evidence suggests the hypertensive elderly should be treated.This publication has 7 references indexed in Scilit:
- Therapeutic choice in the treatment of hypertension: Initial treatment of newly diagnosed hypertension and secular trends in the prescribing of anti hypertensive medications for medicaid patientsThe American Journal of Medicine, 1986
- The Effects of Antihypertensive Therapy on the Quality of LifeNew England Journal of Medicine, 1986
- Systolic Hypertension in the Elderly Program (SHEP): Antihypertensive efficacy of chlorthalidoneThe American Journal of Cardiology, 1985
- Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study.BMJ, 1985
- An Additional Basic Science for Clinical Medicine: II. The Limitations of Randomized TrialsAnnals of Internal Medicine, 1983
- Perspectives on systolic hypertension. The Framingham study.Circulation, 1980
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978